Pancreatic Ductal Adenocarcinoma (PDAC)
Oncology·MeSH: Lung Neoplasms
Prevalence
7.1 / 100K
Incidence
7.5 / 100K/yr
11 drugs in development·8 companies·22 clinical trials
Drug Pipeline by Phase
Phase 3(3)
Phase 2(2)
Phase 1(3)
Preclinical(2)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| Pumitamig | BioNTech SE (BNTX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Pancreatic Ductal Adenocarcinoma (PDAC)?
BioSniper tracks 11 drugs in development for Pancreatic Ductal Adenocarcinoma (PDAC) across 8 companies.
How many clinical trials target Pancreatic Ductal Adenocarcinoma (PDAC)?
There are 22 clinical trials targeting Pancreatic Ductal Adenocarcinoma (PDAC) tracked by BioSniper.
What is the prevalence of Pancreatic Ductal Adenocarcinoma (PDAC)?
The estimated prevalence of Pancreatic Ductal Adenocarcinoma (PDAC) is approximately 7.1 per 100,000 population.
Deep-dive into Pancreatic Ductal Adenocarcinoma (PDAC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis